[{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Inflammatory cascade","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Imperial College London"},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Not Applicable"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NMT-cP12","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Xeno-Skin","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"XenoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Altasciences Company Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Not Applicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"The Virginia Catalyst","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","date":"June 2021","year":"2021","type":"Funding","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ The Virginia Catalyst","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ The Virginia Catalyst"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Transplant Therapy","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RenovaCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tissue-specific pluripotent cells","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray Suspension","sponsorNew":"RenovaCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Genistein","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Erase PTSD"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Avance Clinical"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP705","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
